Trade Galectin Therapeutics Inc. - GALT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.0470 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Galectin Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 3.3565 |
Open* | 3.3465 |
1-Year Change* | 66.94% |
Day's Range* | 3.2465 - 3.4365 |
52 wk Range | 1.08-2.47 |
Average Volume (10 days) | 56.82K |
Average Volume (3 months) | 1.28M |
Market Cap | 107.62M |
P/E Ratio | -100.00K |
Shares Outstanding | 61.85M |
Revenue | N/A |
EPS | -0.76 |
Dividend (Yield %) | N/A |
Beta | 0.80 |
Next Earnings Date | Mar 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 18, 2024 | 3.3365 | -0.0100 | -0.30% | 3.3465 | 3.4365 | 3.2465 |
Apr 17, 2024 | 3.3565 | -0.0400 | -1.18% | 3.3965 | 3.4165 | 3.1565 |
Apr 16, 2024 | 3.3765 | -0.4500 | -11.76% | 3.8265 | 3.8265 | 3.3165 |
Apr 15, 2024 | 3.8665 | 0.0000 | 0.00% | 3.8665 | 3.9365 | 3.7465 |
Apr 12, 2024 | 3.9565 | -0.2500 | -5.94% | 4.2065 | 4.2465 | 3.7465 |
Apr 11, 2024 | 4.1565 | 0.3600 | 9.48% | 3.7965 | 4.1865 | 3.7065 |
Apr 10, 2024 | 3.7865 | -0.1100 | -2.82% | 3.8965 | 4.0865 | 3.6465 |
Apr 9, 2024 | 3.8965 | 0.2000 | 5.41% | 3.6965 | 3.9365 | 3.6565 |
Apr 8, 2024 | 3.7365 | 0.0800 | 2.19% | 3.6565 | 3.7365 | 3.3765 |
Apr 5, 2024 | 3.6865 | 0.6900 | 23.03% | 2.9965 | 3.7065 | 2.9965 |
Apr 4, 2024 | 2.9865 | 0.1300 | 4.55% | 2.8565 | 2.9865 | 2.6065 |
Apr 3, 2024 | 2.7965 | 0.3500 | 14.31% | 2.4465 | 2.9465 | 2.4165 |
Apr 2, 2024 | 2.4965 | 0.1600 | 6.85% | 2.3365 | 2.5665 | 2.3365 |
Apr 1, 2024 | 2.4065 | 0.0300 | 1.26% | 2.3765 | 2.4165 | 2.2965 |
Mar 28, 2024 | 2.3765 | 0.0500 | 2.15% | 2.3265 | 2.3765 | 2.2665 |
Mar 27, 2024 | 2.3865 | 0.0900 | 3.92% | 2.2965 | 2.4165 | 2.2965 |
Mar 26, 2024 | 2.3265 | -0.0200 | -0.85% | 2.3465 | 2.3565 | 2.2365 |
Mar 25, 2024 | 2.3265 | -0.1000 | -4.12% | 2.4265 | 2.4565 | 2.2765 |
Mar 22, 2024 | 2.4265 | -0.0200 | -0.82% | 2.4465 | 2.4465 | 2.2965 |
Mar 21, 2024 | 2.3965 | 0.2000 | 9.11% | 2.1965 | 2.4265 | 2.1965 |
Galectin Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, May 13, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Galectin Therapeutics Inc Earnings Release Q1 2024 Galectin Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, August 12, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q2 2024 Galectin Therapeutics Inc Earnings Release Q2 2024 Galectin Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 38.352 | 30.179 | 23.444 | 13.438 | 13.602 |
Selling/General/Admin. Expenses, Total | 6.615 | 6.361 | 5.468 | 5.971 | 7.131 |
Research & Development | 31.737 | 23.818 | 17.976 | 7.467 | 6.471 |
Operating Income | -38.352 | -30.179 | -23.444 | -13.438 | -13.602 |
Interest Income (Expense), Net Non-Operating | -0.424 | -0.348 | -0.021 | 0.144 | -0.298 |
Net Income Before Taxes | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Net Income After Taxes | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Net Income Before Extra. Items | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Net Income | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Total Adjustments to Net Income | -0.097 | -0.171 | -0.137 | -6.885 | -1.147 |
Income Available to Common Excl. Extra. Items | -38.873 | -30.698 | -23.602 | -20.179 | -15.047 |
Income Available to Common Incl. Extra. Items | -38.873 | -30.698 | -23.602 | -20.179 | -15.047 |
Diluted Net Income | -38.873 | -30.698 | -23.602 | -20.179 | -15.047 |
Diluted Weighted Average Shares | 59.391 | 58.527 | 57.029 | 52.238 | 39.414 |
Diluted EPS Excluding Extraordinary Items | -0.65453 | -0.52451 | -0.41386 | -0.38629 | -0.38177 |
Diluted Normalized EPS | -0.65453 | -0.52451 | -0.41386 | -0.38629 | -0.38177 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 9.003 | 10.342 | 10.633 | 8.122 | 9.662 |
Selling/General/Admin. Expenses, Total | 1.632 | 1.543 | 1.626 | 1.524 | 1.588 |
Research & Development | 7.371 | 8.799 | 9.007 | 6.598 | 8.074 |
Operating Income | -9.003 | -10.342 | -10.633 | -8.122 | -9.662 |
Interest Income (Expense), Net Non-Operating | -0.111 | -1.185 | -0.001 | -0.475 | 0.049 |
Net Income Before Taxes | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Net Income After Taxes | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Net Income Before Extra. Items | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Net Income | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Total Adjustments to Net Income | -0.063 | 0 | -0.065 | 0.016 | -0.064 |
Income Available to Common Excl. Extra. Items | -9.177 | -11.527 | -10.699 | -8.581 | -9.677 |
Income Available to Common Incl. Extra. Items | -9.177 | -11.527 | -10.699 | -8.581 | -9.677 |
Diluted Net Income | -9.177 | -11.527 | -10.699 | -8.581 | -9.677 |
Diluted Weighted Average Shares | 59.582 | 59.48 | 59.424 | 59.396 | 59.389 |
Diluted EPS Excluding Extraordinary Items | -0.15402 | -0.1938 | -0.18005 | -0.14447 | -0.16294 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.15402 | -0.1938 | -0.18005 | -0.14447 | -0.16294 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 20.552 | 41.82 | 29.465 | 48.209 | 8.832 |
Cash and Short Term Investments | 18.592 | 39.648 | 27.142 | 47.48 | 8.253 |
Cash & Equivalents | 18.592 | 39.648 | 27.142 | 47.48 | 8.253 |
Prepaid Expenses | 1.96 | 2.172 | 2.323 | 0.729 | 0.579 |
Total Assets | 21.285 | 41.827 | 29.6 | 48.467 | 9.006 |
Property/Plant/Equipment, Total - Net | 0.086 | 0.007 | 0.048 | 0.084 | 0 |
Property/Plant/Equipment, Total - Gross | 0.081 | 0.122 | 0.158 | 0.074 | |
Accumulated Depreciation, Total | -0.074 | -0.074 | -0.074 | -0.074 | |
Intangibles, Net | 0 | ||||
Total Current Liabilities | 13.012 | 9.033 | 5.399 | 2.82 | 2.108 |
Accounts Payable | 3.89 | 1.805 | 1.292 | 1.661 | 0.297 |
Accrued Expenses | 9.058 | 7.163 | 4.042 | 1.093 | 1.512 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.064 | 0.065 | 0.065 | 0.066 | 0.299 |
Total Liabilities | 53.479 | 39.211 | 5.407 | 2.872 | 2.108 |
Total Long Term Debt | 39.828 | 29.048 | 0 | 0 | 0 |
Total Equity | -32.194 | 2.616 | 24.193 | 45.595 | 6.898 |
Redeemable Preferred Stock | 2.233 | 2.25 | 2.25 | 2.26 | 2.26 |
Preferred Stock - Non Redeemable, Net | 6.682 | ||||
Common Stock | 0.059 | 0.059 | 0.056 | 0.056 | 0.041 |
Additional Paid-In Capital | 275.081 | 271.001 | 261.883 | 259.673 | 194.13 |
Retained Earnings (Accumulated Deficit) | -309.567 | -270.694 | -239.996 | -216.394 | -196.215 |
Total Liabilities & Shareholders’ Equity | 21.285 | 41.827 | 29.6 | 48.467 | 9.006 |
Total Common Shares Outstanding | 59.426 | 59.3413 | 57.0771 | 56.8946 | 41.1909 |
Total Preferred Shares Outstanding | 1.26018 | 1.30268 | 1.30268 | 1.32768 | 6.83568 |
Other Long Term Assets, Total | 0.647 | 0.087 | 0.174 | 0.174 | |
Other Liabilities, Total | 0.639 | 1.13 | 0.008 | 0.052 | |
Long Term Debt | 39.828 | 29.048 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 21.611 | 19.468 | 19.552 | 20.552 | 17.121 |
Cash and Short Term Investments | 20.362 | 17.966 | 17.799 | 18.592 | 15.831 |
Cash & Equivalents | 20.362 | 17.966 | 17.799 | 18.592 | 15.831 |
Prepaid Expenses | 1.249 | 1.502 | 1.753 | 1.96 | 1.29 |
Total Assets | 22.163 | 20.081 | 20.225 | 21.285 | 17.914 |
Property/Plant/Equipment, Total - Net | 0.062 | 0.07 | 0.078 | 0.086 | 0.093 |
Other Long Term Assets, Total | 0.49 | 0.543 | 0.595 | 0.647 | 0.7 |
Total Current Liabilities | 10.522 | 9.953 | 11.533 | 13.012 | 9.588 |
Accounts Payable | 2.681 | 1.976 | 2.553 | 3.89 | 2.352 |
Accrued Expenses | 7.841 | 7.913 | 8.98 | 9.058 | 7.236 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.064 | 0 | 0.064 | 0 |
Total Liabilities | 73.036 | 71.208 | 62.871 | 53.479 | 40.249 |
Total Long Term Debt | 61.14 | 60.359 | 49.941 | 39.828 | 29.734 |
Other Liabilities, Total | 1.374 | 0.896 | 1.397 | 0.639 | 0.927 |
Total Equity | -50.873 | -51.127 | -42.646 | -32.194 | -22.335 |
Redeemable Preferred Stock | 2.233 | 2.233 | 2.233 | 2.233 | 2.233 |
Common Stock | 0.061 | 0.059 | 0.059 | 0.059 | 0.059 |
Additional Paid-In Capital | 291.145 | 276.852 | 276.156 | 275.081 | 274.241 |
Retained Earnings (Accumulated Deficit) | -344.312 | -330.271 | -321.094 | -309.567 | -298.868 |
Total Liabilities & Shareholders’ Equity | 22.163 | 20.081 | 20.225 | 21.285 | 17.914 |
Total Common Shares Outstanding | 61.8487 | 59.5822 | 59.5822 | 59.426 | 59.426 |
Total Preferred Shares Outstanding | 1.26018 | 1.26018 | 1.26018 | 1.26018 | 1.26018 |
Long Term Debt | 61.14 | 60.359 | 49.941 | 39.828 | 29.734 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Cash From Operating Activities | -31.056 | -24.308 | -20.601 | -10.848 | -10.179 |
Cash From Operating Activities | 0 | ||||
Non-Cash Items | 2.752 | 2.468 | 1.922 | 1.805 | 4.793 |
Changes in Working Capital | 4.968 | 3.751 | 0.942 | 0.641 | -1.072 |
Cash From Investing Activities | 0 | 0 | 0 | ||
Capital Expenditures | 0 | ||||
Cash From Financing Activities | 10 | 36.814 | 0.263 | 50.075 | 15.379 |
Issuance (Retirement) of Stock, Net | 0 | 6.814 | 0.263 | 50.469 | 15.379 |
Net Change in Cash | -21.056 | 12.506 | -20.338 | 39.227 | 5.2 |
Total Cash Dividends Paid | 0 | -0.394 | |||
Other Investing Cash Flow Items, Total | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | 10 | 30 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.527 | -38.776 | -28.142 | -19.545 | -9.932 |
Cash From Operating Activities | -10.793 | -31.056 | -23.817 | -15.47 | -8.042 |
Non-Cash Items | 1.607 | 2.752 | 2.206 | 1.176 | 0.719 |
Changes in Working Capital | -0.873 | 4.968 | 2.119 | 2.899 | 1.171 |
Cash From Financing Activities | 10 | 10 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -0.793 | -21.056 | -23.817 | -15.47 | -8.042 |
Issuance (Retirement) of Debt, Net | 10 | 10 | 0 | 0 | |
Cash From Investing Activities | 0 | ||||
Other Investing Cash Flow Items, Total | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Galectin Therapeutics Inc. Company profile
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).
Equity composition
Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.
Industry: | Biotechnology & Medical Research (NEC) |
Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com